Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Fortrea Holdings Inc. (FTRE)

25.88 +1.45 (+5.94%)
At close: October 28 at 4:00:00 PM EDT
25.91 +0.03 (+0.10%)
Pre-Market: 4:46:50 AM EDT
Trade FTRE on Coinbase
FTRE Q3 2026 earnings call
Today at 8 AM EDT
Chart Range Bar
Loading chart for FTRE
  • Previous Close 24.43
  • Open 24.36
  • Bid 18.74 x 200
  • Ask 31.23 x 200
  • Day's Range 24.30 - 26.16
  • 52 Week Range 8.55 - 26.16
  • Volume 3,587,141
  • Avg. Volume 1,615,710
  • Market Cap (intraday) 2.461B
  • Beta (5Y Monthly) 1.91
  • PE Ratio (TTM) --
  • EPS (TTM) -0.91
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 21.71
  • Morningstar Rating Rating available with Stock Picks access

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

www.fortrea.com

14,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FTRE
50.03%
S&P 500 (^GSPC)
13.13%

1-Year Return

FTRE
143.69%
S&P 500 (^GSPC)
12.38%

3-Year Return

FTRE
5.99%
S&P 500 (^GSPC)
88.08%

5-Year Return

FTRE
14.02%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 678.2M
Earnings -13.2M
Profit Margin -1.95%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
-4.0%
-3.0%
-2.0%

Analyst Insights

View More

Analyst Price Targets

13.50 Low
21.71 Average
25.88 Current
26.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/20/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 22 -> 24

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.18%

  • Return on Assets (ttm)

    0.58%

  • Return on Equity (ttm)

    -15.30%

  • Revenue (ttm)

    2.68B

  • Net Income Avi to Common (ttm)

    -85.2M

  • Diluted EPS (ttm)

    -0.91

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    168.6M

  • Total Debt/Equity (mrq)

    213.24%

  • Levered Free Cash Flow (ttm)

    278.86M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: